Chile Menopause Drugs Market Analysis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF CHILE MENOPAUSE DRUGS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 CHILE MENOPAUSE DRUGS MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 COUNTRY SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 CAUSE SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 EPIDEMIOLOGY

4.2 PESTEL'S MODEL

4.3 PORTER'S FIVE FORCES MODEL

5 PIPELINE ANALYSIS FOR CHILE MENOPAUSE DRUGS MARKET

6 CHILE MENOPAUSE DRUGS MARKET, COUNTRY SUMMARY

6.1 OVERVIEW

7 CHILE MENOPAUSE DRUG TREATMENT MARKET: REGULATORY SCENARIO

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 LOW AGE OF MENOPAUSE DISORDER OCCURRENCE AS COMPARED TO OTHER REGIONS

8.1.2 RISE IN AGEING POPULATION AMONG WOMEN IN CHILE

8.1.3 RISE IN RESEARCH AND DEVELOPMENT

8.1.4 RISE IN PHYSICAL INACTIVITY AND SEDENTARY LIFESTYLE

8.1.5 REIMBURSEMENT FOR MENOPAUSE TREATMENT

8.2 RESTRAINTS

8.2.1 RISE IN COST OF THE MENOPAUSE DRUGS

8.2.2 PATENT EXPIRY

8.2.3 COMPLEXITY IN MENOPAUSE

8.2.4 LACK OF AWARENESS ABOUT MENOPAUSE

8.3 OPPORTUNITIES

8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS

8.3.2 RISE IN HEALTHCARE EXPENDITURE

1.3.2 PRESENCE OF A STRONG PRODUCT PIPELINE

8.4 CHALLENGES

8.4.1 ADVERSE EFFECTS OF MEDICATION

8.4.2 AVAILABILITY OF ALTERNATIVES

9 IMPACT OF COVID-19 ON CHILE MENOPAUSE DRUG TREATMENT MARKET

9.1 IMPACT ON PRICE

9.2 IMPACT ON SUPPLY CHAIN

9.3 IMPACT ON DEMAND

9.4 STRATEGIC DECISIONS FOR MANUFACTURERS

9.5 CONCLUSION

10 CHILE MENOPAUSE DRUGS MARKET, BY STAGES

10.1 OVERVIEW

10.2 POSTMENOPAUSE

10.3 PERIMENOPAUSE

10.4 MENOPAUSE

11 CHILE MENOPAUSE DRUGS MARKET, BY TYPE

11.1 OVERVIEW

11.2 NON-HORMONAL THERAPY

11.2.1 MEDICATION

11.2.1.1 ANTI-DEPRESSANTS

11.2.1.2 PAROXETINE

11.2.1.3 GABAPENTIN

11.2.1.4 CLONIDINE

11.2.1.5 OSPEMIFENE

11.2.1.6 OTHERS

11.2.2 SUPPLEMENTS

11.2.2.1 HERBAL SUPPLEMENTS

11.2.2.1.1 GINSENG

11.2.2.1.2 ASHWAGANDHA

11.2.2.1.3 OTHERS

11.2.2.2 VITAMIN D

11.2.2.3 OTHERS

11.3 HORMONAL THERAPY

11.3.1 ESTROGEN

11.3.1.1 17 B- ESTRADIOL

11.3.1.2 CONJUGATED ESTROGEN

11.3.1.3 ESTRADIOL HEMIHYDRATE

11.3.1.4 ESTERIFIED ESTROGEN

11.3.1.5 ESTERIFIED ACETATE

11.3.1.6 ESTROPIPATE

11.3.1.7 OTHERS

11.3.2 COMBINES ESTROGEN & PROGESTOGEN DRUGS

11.3.2.1 17 B- ESTRADIOL (E) + NORETHINODRONE ACETATE (P)

11.3.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P)

11.3.2.3 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P)

11.3.2.4 OTHERS

11.3.3 MEDROXYPROGESTERONE ACETATE

12 CHILE MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS

12.1 OVERVIEW

12.2 VASOMOTOR SYMPTOMS

12.2.1 HORMONAL THERAPY

12.2.2 NON-HORMONAL THERAPY

12.3 ATROPHIC VAGINITIS

12.3.1 HORMONAL THERAPY

12.3.2 NON-HORMONAL THERAPY

12.4 DYSPAREUNIA

12.4.1 HORMONAL THERAPY

12.4.2 NON-HORMONAL THERAPY

12.5 OSTEOPOROSIS

12.5.1 NON-HORMONAL THERAPY

12.5.2 HORMONAL THERAPY

12.6 DEPRESSION

12.6.1 NON-HORMONAL THERAPY

12.6.2 HORMONAL THERAPY

12.7 JOINT PAIN

12.7.1 NON-HORMONAL THERAPY

12.7.2 HORMONAL THERAPY

12.8 WEIGHT GAIN

12.8.1 HORMONAL THERAPY

12.8.2 NON- HORMONAL THERAPY

12.9 OTHERS

13 CHILE MENOPAUSE DRUGS MARKET, BY DOSAGE FORM

13.1 OVERVIEW

13.2 TABLET

13.3 CREAM

13.4 PATCH/FILM

13.5 RINGS

13.6 GEL

13.7 INJECTION SHOT

13.8 SPRAY

13.9 OTHERS

14 CHILE MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION

14.1 OVERVIEW

14.2 ORAL

14.3 PARENTERAL

14.3.1 INTRAVENOUS

14.3.2 SUBCUTANEOUS

14.3.3 OTHERS

14.4 TRANSDERMAL

14.5 VAGINAL

14.6 OTHERS

15 CHILE MENOPAUSE DRUGS MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 CLINICS

15.4 HOME HEALTHCARE

15.5 OTHERS

16 CHILE MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 RETAIL PHARMACY

16.3 HOSPITAL PHARMACY

16.4 ONLINE PHARMACY

17 CHILE MENOPAUSE DRUGS MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: CHILE

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 BAYER AG

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 PRODUCT PORTFOLIO

19.1.4 RECENT DEVELOPMENTS

19.2 PFIZER INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 PRODUCT PORTFOLIO

19.2.4 RECENT DEVELOPMENTS

19.3 NOVARTIS AG

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 PRODUCT PORTFOLIO

19.3.4 RECENT DEVELOPMENT

19.4 TEVA PHARMACEUTICAL INDUSTRIES LTD

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 PRODUCT PORTFOLIO

19.4.4 RECENT DEVELOPMENTS

19.5 KNOP LABORATORIES

19.5.1 COMPANY SNAPSHOT

19.5.2 PRODUCT PORTFOLIO

19.5.3 RECENT DEVELOPMENTS

19.6 SAVAL PHARMACEUTICALS

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 ITF-LABOMED FARMACEUTICA LTDA.

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENTS

19.8 TECNOFARMA S.A.

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 MEGALABS CHILE S.A

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENTS

19.1 ABBVIE INC.

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENTS

19.11 ABBOTT (2021)

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 FRESENIUS KABI CHILE

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 GLAXO SMITH KLINE PLC(2021)

19.13.1 COMPANY SNAPSHOT

19.13.2 REVENUE ANALYSIS

19.13.3 PRODUCT PORTFOLIO

19.14 LABORATORIOS MAVER

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENTS

19.15 NOVO NORDISK A/S

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 SYNTHON

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS